An HPV testing workflow needs more than a sensitive amplification reagent. It needs consistent nucleic acid recovery, a readout matched to the question, and components that work together from sample preparation to detection. HPV DNA genotyping identifies viral genetic material, while E6/E7 mRNA testing adds information about viral oncogene expression. Yeasen offers extraction reagents, qPCR and one-step RT-qPCR systems, enzymes, and instruments to support both approaches.

Why HPV Testing Needs More Than One Readout

Cervical cancer prevention starts with one well-established fact: nearly all cervical cancers—99.7% in a landmark global study—are linked to human papillomavirus (HPV). Just four types (HPV 16, 18, 45, and 31) cause about 80% of cases, and lifetime exposure is common, affecting an estimated 70–80% of sexually active women.

The good news: the disease moves slowly. Persistent high-risk infection can stay silent for years—often 10 to 15 years or more—before precancerous changes appear. That's a wide window for early detection, if the right test is available.

The limitation of DNA testing

HPV DNA genotyping is the established backbone of screening programs, including those supporting NMPA submissions in China. But a positive DNA result only tells you the virus is there. It can't tell a transient infection from a persistent one with cancer-causing potential. High sensitivity is a strength—but it also creates a triage problem: which positives actually need follow-up?

What E6/E7 mRNA adds

HPV-driven cancer depends on two viral oncogenes: E6 degrades the tumor suppressor p53, while E7 disrupts the pRb pathway. Together, they derail cell-cycle control and drive genomic instability. E6/E7 mRNA testing measures whether these oncogenes are actively transcribed—shifting the question from "Is the virus present?" to "Is it doing damage?"

In practice, detecting HPV DNA may simply reflect a transient infection rather than ongoing disease or cancer risk. E6/E7 mRNA, by contrast, is closely associated with viral genome integration, transcriptional activity, and persistent infection—making it a marker of "lesion" rather than mere "infection." This distinction helps identify precancerous lesions at risk of progressing to invasive cancer, while sparing patients with transient infections and benign findings from over-testing and unnecessary treatment.

Figure 1. Schematic diagram of HPV infection in cervical cells[2].

Figure 1. Schematic diagram of HPV infection in cervical cells[2].

A two-signal strategy

The direction of travel is global. The 2025 Chinese Expert Consensus now recognizes E6/E7 mRNA as a tool for screening and triage, alongside HPV DNA testing. WHO has suggested that HPV mRNA detection may serve as an alternative primary screening method—albeit as a conditional recommendation, with HPV DNA remaining the preferred test—and IARC is currently reviewing mRNA versus DNA assays through a formal expert working group. In the US, E6/E7 mRNA assays are FDA-cleared for co-testing and ASC-US triage, though not yet for standalone primary screening. For assay developers, the message is consistent across markets: pairing DNA detection with an E6/E7 mRNA readout reflects where cervical cancer screening policy is heading.

Start with robust DNA genotyping

Yeasen Hieff Unicon™ Robust Multiplex qPCR PreMix V1 (UDG Plus)(Cat#16945ES) is a liquid formulation for HPV DNA assay development. Its next-generation antibody-based hot-start Taq is designed to suppress both 5′→3′ polymerase activity and 5′→3′ exonuclease activity before activation, supporting a controlled hot start and clean release of enzyme activity. The formulation tolerates inhibitors, is compatible with nucleic acid release reagents, and supports direct amplification from oral swabs.

Figure 2. HPV amplification comparison between 16945 and a competitor reagent. Mixed plasmid targets and individual plasmid targets cover 12 HPV types. All original amplification traces are retained.

Figure 2. HPV amplification comparison between 16945 and a competitor reagent. Mixed plasmid targets and individual plasmid targets cover 12 HPV types. All original amplification traces are retained.

The reported comparison tested a mixture of plasmids representing 12 HPV types at 10⁻⁷ and 10⁻⁹ dilutions, as well as individual plasmid targets at a 10⁻⁷ dilution. Both reagents detected the tested types without missed targets in this experiment. Low-concentration detection and amplification curve profiles were comparable, supporting the use of 16945 in HPV genotyping assay development.

Choose a Lyophilization-Ready Format When the Assay Needs It

Hifair™ Lyo-Ready Robust Multiplex qPCR Kit (UDG plus)(CaT#16940ES) uses a formulation with very low glycerol, low salt, and a lyoprotectant system. It supports different freeze-dried formats, including in situ lyophilization and lyophilized microcores, to simplify storage and transport at ambient temperature after suitable formulation and stability validation. The system also supports a fully premixed 5 µL reaction format and low-copy target detection.

Table 1. Reported comparison of 16940 lyophilized microcores with a competitor reagent in 98 HPV clinical samples.

Sample

Comparison

Count

HPV clinical samples

Detected with 16940

98

Detected with supplier B* reagent

98

Ct: 16940 < supplier B*

43

Ct: 16940 = supplier B*

24

Ct: 16940 > supplier B*

31

Both reagents detected all 98 samples in the reported comparison. The Ct value with 16940 was lower in 43 samples, equal in 24, and higher in 31. Together, these counts show the Ct distribution within the tested sample set.

Add E6 and E7 mRNA Detection with One-Step RT-qPCR

RNA assays need speed, stability, and contamination control. Yeasen’s one-step RT-qPCR(Cat#16630) approach combines reverse transcription and quantitative PCR in a single reaction. Reducing separate handling steps simplifies setup, shortens turnaround, and reduces opportunities for contamination introduced during multiple transfers.

Paired with melting-curve analysis, the system can distinguish multiple HPV RNA targets within one tube. This combines the convenience of one-step amplification with an additional route to multiplex discrimination for HPV assay development.

Figure 3. Representative amplification results of the 14‑type HPV RNA panel. FAM, HEX, and ROX correspond to Panel 1, Panel 6 and Panel 10, respectively. Group A: Supplier C* reagent; Group B: 16630.

Figure 3. Representative amplification results of the 14‑type HPV RNA panel. FAM, HEX, and ROX correspond to Panel 1, Panel 6 and Panel 10, respectively. Group A: Supplier C* reagent; Group B: 16630.

The test utilized 14-type HPV RNA reference templates (100, 20, 10 copies/µL) plus an internal control. Parallel melting‑curve analysis is displayed for one representative target per channel. 16630 demonstrated superior low‑copy sensitivity and clear Tm separation for robust multiplex target identification.

Build on an Integrated Enzyme and Reagent Platform

As HPV screening programs expand worldwide, assay developers face a common challenge: securing a reliable, scalable supply of high-quality reagents that can support everything from early R&D to commercial production. Yeasen's Zyme Editor™ platform has supported engineering of more than 130 molecular enzymes, with ISO 13485-based manufacturing scaling from 5 L to 1,500 L. The portfolio spans reverse transcriptases, RNase inhibitors, Taq polymerases, UDG/UNG, Taq antibodies, and dNTPs, plus optimized qPCR and RT-qPCR premixes—with customization from single components to complete reaction systems. Together, these cover automated extraction, magnetic bead purification, liquid and lyophilization-ready DNA amplification, RNA amplification, and methylation-related assays: the building blocks for connecting the entire HPV testing workflow, from sample input to result.

Products for an HPV Testing Workflow

Category

Application

Product

Cat. No.

Instrument

Automated nucleic acid extraction

96-Channel Automated Nucleic Acid Extraction Instrument

80510ES

Sample preparation

Magnetic bead nucleic acid extraction

Magnetic Pathogen DNA/RNA Extraction Kit

18306ES

qPCR Mix

HPV DNA testing

Hieff Unicon™ Robust Multiplex qPCR PreMix V1 (UDG Plus)

16945ES

HPV DNA testing; lyophilization-ready

Hifair™ Lyo-Ready Robust Multiplex qPCR Kit (UDG plus)

16940ES

HPV methylation-related assays

BioSensitive MethyProbe qPCR Master Mix

16701ES

RT-qPCR Kit

HPV RNA testing

Hifair™ C203P1 Multiplex One Step RT-qPCR Probe Kit (UDG Plus)

16630ES

Molecular Enzyme

Reverse transcription for E6/E7 mRNA

Hifair UCF. ME™ Advanced Reverse Transcriptase (200 U/µL)

14614ES

Taq enzyme

Hieff Unicon™ Robust Hotstart Taq DNA Polymerase (20 U/µL)

14325ES

RNase inhibition

Murine RNase Inhibitor (40 U/µL)

10603ES

Instrument

Real-time quantitative PCR analysis

Celemetor™ Real-Time Quantitative PCR Analysis System

80521ES

Consumable

-

Nucleic Acid Remover

19702ES

Reference

[1] Ndiaye C, Mena M, Alemany L, et al. HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis[J]. The Lancet Oncology, 2014, 15(12): 1319-1331.

[2] Broccolo F, Fusetti L, Rosini S, et al. Comparison of oncogenic HPV type‐specific viral DNA load and E6/E7 mRNA detection in cervical samples: results from a multicenter study[J]. Journal of medical virology, 2013, 85(3): 472-482.

Enquête